FIELD: medicine.
SUBSTANCE: invention refers to chelating agents and their technetium complexes to be used as radiopharmaceuticals and characterised by formula I where X is -NR-, -CO2-, -CO-, -NR(C=S)-, -NR(C=O)-, -CONR- or Q; Y represents amino acid, -CH2-, -CH2OCH2-, -OCH2CH2O- or X; Z is an aggregation from peptides, their analogues, substrata, antagonists or enzyme inhibitors, receptor-bonding compounds, oligonucleotides, oligo-DNA- or oligo-RNA-fragments; n is a number 1 to 8; m is a number 0 to 30; R represents H, C1-4alkyl, C2-4alkoxyalkyl, C1-4hydroxyalkyl or C1-4fluoroalkyl; Q represents remains of succinimide , A is a pharmaceutically acceptable anion.
EFFECT: production of new chelating agents applicable for making the technetium complexes.
22 cl, 12 ex, 3 dwg, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
IMPROVED CHELATE CONJUGATES | 2002 |
|
RU2298012C2 |
PRIMER FOR Tc BASED RADIOPHARMACEUTICALS PRODUCTION | 2015 |
|
RU2614695C2 |
COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
RADIOACTIVE ISOTOPE-LABELLED CONJUGATES OF RGD-CONTAINING PEPTIDES AND METHODS OF OBTAINING SAID CONJUGATES USING CLICK CHEMISTRY | 2005 |
|
RU2419627C2 |
VISUALISATION TECHNIQUE | 2008 |
|
RU2505316C2 |
COMPLEXES OF METALS WITH BICYCLOPOLYAZAMACROCYCLE, METHOD OF THEIR SYNTHESIS AND A PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF PATIENTS WITH CANCER | 1992 |
|
RU2118325C1 |
CYCLIC PEPTIDES, RADIOPHARMACEUTICAL PREPARATION, AND RADIOACTIVELY LABELED CYCLIC PEPTIDES | 1994 |
|
RU2145608C1 |
TECHNETIUM AND RHENIUM COMPLEXES WITH BIS(HETEROARYLS) AND METHODS FOR USING THEM | 2009 |
|
RU2539584C2 |
PEPTIDE COMPOUND CAPABLE OF BINDING WITH PSMA, METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2823164C2 |
GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
Authors
Dates
2009-07-10—Published
2005-07-19—Filed